Nicole Bajic, MD
Ophthalmology · Independence, OHNPI 1922410471
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,080 of the $51,505 with a category attached, or 68.1%. 24 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 29.3% of the total. 2025 is the largest year on record at $26,074, more than ten times the $541 reported in 2019. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $375.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$15K
- Carl Zeiss Meditec USA, Inc.$11K
- Johnson & Johnson Surgical Vision, Inc.$9K
- Dompe US, Inc.$6K
- Alcon$3K
- NEW World Medical,inc.$2K
- plus $5K from 18 others
Across 2 payments — averaging $2310.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$5K
What the payments were for
- Consulting fees$35,08068%
- Speaking & faculty fees$8,02516%
- Travel & lodging$6881%
- Food & beverage$7,71215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 17 | $15,114 |
| Carl Zeiss Meditec USA, Inc. | 15 | $10,978 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $9,332 |
| Dompe US, Inc. | 11 | $5,640 |
| Alcon | 27 | $3,283 |
| NEW World Medical,inc. | 11 | $2,065 |
| AbbVie(2 entities) | 6 | $1,666 |
| Tarsus Pharmaceuticals, Inc. | 4 | $1,142 |
| Alcon Research LLC | 1 | $400 |
| Bausch & Lomb Americas Inc. | 4 | $291 |
| Boston Scientific | 2 | $236 |
| Dendreon Pharmaceuticals LLC | 3 | $226 |
| Sight Sciences, Inc. | 2 | $209 |
| Ocular Therapeutix, Inc. | 3 | $173 |
| Beaver-visitec International, Inc. | 1 | $163 |
| Aerie Pharmaceuticals, Inc. | 3 | $152 |
| Nova Eye, Inc. | 1 | $120 |
| Thea Pharma Inc. | 1 | $115 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| Biotissue Holdings Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Glaukos Corporation | 1 | $26 |
| Antares Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALLISTO eye$12,125
- CIRRUS HD-OCT$11,900
- QUATERA 700$10,655
- Tecnis IOL$8,906
- Compact Intuitiv$8,800
- Healon Duet Pro$8,800
- VisuMax$8,430
- CIRRUS 6000 with AngioPlex$8,250
- VERACITY SURGICAL$6,280
- IOLMaster 700$6,060
- Oxervate$5,350
- MEL 90$4,500
- FORUM$3,325
- Humphrey HFA$3,325
- ARTEVO 800$3,157
- CLARUS$2,250
- ATLAS 500$2,250
- FORUM Glaucoma Workplace$2,200
- Cataract Suite$1,775
- Kahook Dual Blade$1,700
How this compares
$51,505 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 46 | $47,533 |
| Restasis MultidoseCyclosporine | 62 | $37,826 |
| Prednisolone Acetate | 393 | $19,554 |
| Cyclosporine | 29 | $14,478 |
| MieboPerfluorohexyloctane/Pf | 19 | $13,746 |
| Ketorolac Tromethamine | 122 | $2,744 |
| Latanoprost | 235 | $2,442 |
| Fluorometholone | 15 | $1,366 |
| ErythromycinErythromycin Base | 62 | $708 |
| Timolol Maleate | 55 | $659 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 47 | $485 |
| Doxycycline Monohydrate | 28 | $469 |
| Brimonidine Tartrate | 55 | $403 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $369 |
| Ciprofloxacin Hcl | 11 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $1,666 | $85,359108 claims |
| Bausch & Lomb Americas Inc.Miebo | $291 | $13,74619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Independence
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.